IP Verse

Dr Reddys Laboratories Betapharm Arzneimittel competitive analysis

Loading summary...

Latest oppositions filed by Dr Reddys Laboratories Betapharm Arzneimittel

Explore patent oppositions filed by Dr Reddys Laboratories Betapharm Arzneimittel against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2959894
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 12, 2023
EP2493466
Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMAMar 31, 2021
EP3294285
Cabazitaxel And Its Use For Treating CancerAVENTIS PHARMAAug 26, 2020
EP3351246
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTISJan 29, 2020
EP3342411
Rapamycin Derivative For Treating Pancreas CancerNOVARTISAug 27, 2019
EP3078667
Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICAAug 20, 2019

Latest publications and patents of Dr Reddys Laboratories Betapharm Arzneimittel New

Explore the latest publications and patents granted to Dr Reddys Laboratories Betapharm Arzneimittel, showcasing their recent innovations and technological advancements.

Latest PTAB cases involving Dr Reddys Laboratories Betapharm Arzneimittel

Discover the latest PTAB cases involving Dr Reddys Laboratories Betapharm Arzneimittel, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Dr Reddys Laboratories Betapharm Arzneimittel with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTEL6 - - -
AVENTIS PHARMA - 24 - 3
NOVARTIS6422 - 21
SANOFI MATURE - 24 - -